2-Chloro-N-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetamide

Catalog No. :
ACNLFX507
CAS No. :
379254-84-9
Molecular Formula :
C8H10ClN3O3
Molecular Weight :
231.64

IUPAC Name:2-chloro-N-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetamide

2-Chloro-N-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$155.00Login to see priceInquiryInquiry
1g95%$387.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Chloro-N-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetamide
IUPAC Name2-chloro-N-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetamide
Molecular FormulaC8H10ClN3O3
Molecular Weight231.64
SMILESO=C(NC(N(C)C1=O)=CC(N1C)=O)CCl
InChI KeyHMSZMICYINCVMI-UHFFFAOYSA-N
SynonymTIMTEC-BB SBB007477;2-CHLORO-N-(1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-PYRIMIDIN-4-YL)-ACETAMIDE;2-chloro-N-(1,3-dimethyl-2,6-dioxo-4-pyrimidinyl)acetamide;Acetamide, 2-chloro-N-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-;BAS 01332381;SBB007477;ZINC01287285;2-chloro-N-(1,3-dimethyl-2,6-dioxo-pyrimidin-4-yl)acetamide
CAS No.379254-84-9

Synthetic Route by SureRoute

1. ACNLFX507 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRMJD712 route compound structure diagram
    ACRMJD7126642-31-5 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNLFX507 route product structure diagram
    ACNLFX507379254-84-9
Inquiry

2. ACNLFX507 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRMJD712 route compound structure diagram
    ACRMJD7126642-31-5 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNLFX507 route product structure diagram
    ACNLFX507379254-84-9
Inquiry

Comments (0)